Reality Check on Epilepsy
Market access for epilepsy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, almost 31% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In January 2020, the FDA approved Neurelis, Inc.’s Valtoco (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are different from usual seizure patterns in people at least 6 years old with epilepsy
- Key Findings: Many generic options are used in the treatment of seizures. New players have emerged, but big prescription sales are illusive in comparison with previous generic and brand antiepileptic drugs
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.